Skip to main content
Medtronic reports positive results from DCB study in dialysis patients

A study of Medtronic's drug-coated balloon in dialysis patients demonstrated an 86.1% likelihood the vessel would remain open versus 68.9% in the percutaneous transluminal angioplasty control group. The data show the device could be beneficial for high-risk patients, said Mark Pacyna, vice president of Medtronic's peripheral vascular business.

Full Story: